ACHV — Achieve Life Sciences Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.06 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
Directors
- Richard Stewart CHM (61)
- Cindy Jacobs PRE (62)
- John Bencich CEO (42)
- Jerry Wan (38)
- Anthony Clarke CSO (64)
- Scott Cormack DRC (55)
- Bridget Martell
- Donald Joseph (66)
- Martin Mattingly (63)
- Jay Moyes
- H. Stewart Parker (65)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- March 22nd, 1995
- Public Since
- October 12th, 1995
- No. of Shareholders
- 9,885
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 9,007,060
- Address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, 98021
- Web
- http://achievelifesciences.com/
- Phone
- +1 4256861500
- Contact
- Jason Wong
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ACHV
Upcoming events for ACHV
Q3 2021 Achieve Life Sciences Inc Earnings Release
Similar to ACHV
ABEONA THERAPEUTICS ORD
NASDAQ Capital Market
ACASTI PHARMA CL A ORD
NASDAQ Capital Market
ACURX PHARMACEUTICALS ORD
NASDAQ Capital Market
ADDEX THERAPEUTICS ADR
NASDAQ Capital Market
ADVAXIS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:54 UTC, shares in Achieve Life Sciences are trading at $6.83. This share price information is delayed by 15 minutes.
Shares in Achieve Life Sciences last closed at $6.83 and the price had moved by -26.08% over the past 365 days. In terms of relative price strength the Achieve Life Sciences share price has underperformed the S&P500 Index by -43.92% over the past year.
The overall consensus recommendation for Achieve Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Achieve Life Sciences does not currently pay a dividend.
Achieve Life Sciences does not currently pay a dividend.
Achieve Life Sciences does not currently pay a dividend.
To buy shares in Achieve Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.83, shares in Achieve Life Sciences had a market capitalisation of $61.52m.
Here are the trading details for Achieve Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACHV
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Achieve Life Sciences does not currently have a style classification.
The analyst consensus target price for shares in Achieve Life Sciences is $42.83. That is 527.09% above the last closing price of $6.83.
Analysts covering Achieve Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$4.39 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Achieve Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -56.06%.
As of the last closing price of $6.83, shares in Achieve Life Sciences were trading -29.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Achieve Life Sciences.
Achieve Life Sciences' management team is headed by:
- Richard Stewart - CHM
- Cindy Jacobs - PRE
- John Bencich - CEO
- Jerry Wan -
- Anthony Clarke - CSO
- Scott Cormack - DRC
- Bridget Martell -
- Donald Joseph -
- Martin Mattingly -
- Jay Moyes -
- H. Stewart Parker -
We do not have data on Achieve Life Sciences' shareholders